Bristol-Myers Squibb

5 Biotech Stocks With Big News Due In January
Investors.com
Wed, 12/31/14 - 05:15 pm
Celgene
Biogen Idec
Gilead Sciences
AbbVie
Vertex Pharmaceuticals
Bristol-Myers Squibb
Who will win the Opdivo-Keytruda coverage clash?
Medical Marketing and Media
Tue, 12/30/14 - 10:29 am
Opdivo
Keytruda
Merck
Bristol-Myers Squibb
The Most Important New Drug Of 2014
Forbes
Tue, 12/30/14 - 10:15 am
Ketruda
Merck
Opdivo
Bristol-Myers Squibb
5 Top Pharmaceutical Stock Picks for 2015
24/7 Wall St
Mon, 12/29/14 - 10:52 am
Merck
Bristol-Myers Squibb
Eli Lilly
Shire
Flamel
4 Potential Blockbuster Drugs The FDA Just Approved
Investors.com
Fri, 12/26/14 - 10:11 pm
Bristol-Myers Squibb
Opdivo
Merck
Cubist Pharmaceuticals
Zerbaxa
AstraZeneca
Lynparza
Novo Nordisk
Saxenda
A new era of immuno-oncology has arrived
Fierce Biotech
Fri, 12/26/14 - 10:17 am
immuno-oncology
Merck
Keytruda
Bristol-Myers Squibb
Opdivo
Roche
Amgen
AstraZeneca
Early Opdivo OK gives BMS more time to erase Keytruda's lead
Medical Marketing and Media
Wed, 12/24/14 - 09:29 am
Opdivo
Bristol-Myers Squibb
Keytruda
melanoma
FDA approves Bristol-Myer's skin cancer drug
Yahoo/Reuters
Mon, 12/22/14 - 04:44 pm
FDA
Opdivo
Bristol-Myers Squibb
melanoma
J.P. Morgan's 6 Top Biotech and Pharmaceuticals Stocks to Buy in 2015
TheStreet.com
Mon, 12/22/14 - 09:47 am
Alexion
Biomarin
Bristol-Myers Squibb
Jazz Pharmaceuticals
Valeant Pharmaceuticals
Illumina
The top 10 patent losses of 2015
Fierce Pharma
Fri, 12/19/14 - 08:35 am
patents
Lantus
Abilify
Copaxone
Neulasta
Tracleer
Namenda
Avodart
Jalyn
Zyvox
Androgel
Synagis
Sanofi
Bristol-Myers Squibb
Otsuka
Teva Pharmaceutical
Amgen
Actelion
Actavis
GSK
Pfizer
AbbVie
AstraZeneca
2015 Biotech Drug/Stock Outlook: Here's What You Need to Know
TheStreet.com
Wed, 12/17/14 - 10:02 am
Biogen Idec
Bluebird Bio
Arrowhead Research
Vertex Pharmaceuticals
Cempra
CTI BioPharma
Gilead Sciences
Merck
Bristol-Myers Squibb
Sarepta Therapeutics
Neurocrine Biosciences
Drug makers face another $65 billion patent cliff
Marketwatch
Wed, 12/10/14 - 05:37 pm
patents
patent cliff
Pfizer
Otsuka
AstraZeneca
Bristol-Myers Squibb
The 7 Most Important Drug-Stock Lessons From This Weekend's Blood Cancer Meeting
TheStreet.com
Mon, 12/8/14 - 10:30 am
Agios Pharmaceuticals
Novartis
CAR-T
Celgene
Amgen
Merck
Bristol-Myers Squibb
Seattle Genetics
Sunesis
Will Pfizer End Up Buying Bristol-Myers Squibb As Its Interest In AstraZeneca Fades?
Bidness Etc.
Mon, 12/8/14 - 08:01 am
Pfizer
Bristol-Myers Squibb
AstraZeneca
M&A
Opdivo (nivolumab) Demonstrates High Overall Response Rate of 87% for Treatment of Relapsed or Refractory Hodgkin Lymphoma
Yahoo/BusinessWire
Sun, 12/7/14 - 10:11 am
Opdivo
Hodgkin's lymphoma
Bristol-Myers Squibb
Bristol-Myers Squibb Foundation Awards Nine Grants Totaling More than $3.5 Million to Support Care for High-Risk Patients with Hepatitis B and C in China and India
Yahoo
Wed, 12/3/14 - 10:03 am
Bristol-Myers Squibb
India
grants
hepatitis B
hepatitis C
Bristol-Myers Cuts Jobs in China as Drug Makers Rethink Marketing
WSJ Pharmalot
Mon, 12/1/14 - 11:22 am
Bristol-Myers Squibb
China
layoffs
Bristol-Myers Squibb and Pfizer Inc.'s Bet on This Small Biotech Stock Could Pay Off
Motley Fool
Mon, 12/1/14 - 09:12 am
Pfizer
Bristol-Myers Squibb
Portola Pharmaceuticals
andexanet alfa
FDA declines to approve Bristol-Myers hepatitis drug
Yahoo/Reuters
Wed, 11/26/14 - 12:08 pm
hepatitis C
Bristol-Myers Squibb
FDA
daclatasvir
Five Prime gets $30M upfront from Bristol-Myers and will study combination cancer treatment
Yahoo/AP
Mon, 11/24/14 - 06:03 pm
Five Prime
Bristol-Myers Squibb
Opdivo
FPA008
melanoma

Pages